August 03, 2016
The global biomarkers market is expected to reach over $78.2 billion by 2024, according to a new report by Grand View Research, Inc.
The reports key finding state that
• the safety biomarkers segment held the largest share of over 40% in 2015
• the validation biomarkers segment is determined as one of the fastest growing segments
• the drug discovery segment dominated the application segment in 2015
• the cardiovascular segment is expected to be the fastest growing segment with a CAGR of over 14.0%
• North America held the largest regional share of around 39% in 2015
• Asia Pacific is anticipated to be the fastest growing biomarker market owing to the factors, such as the developing economic conditions, a large base of the target population, and a favorable regulatory scenario for clinical trials.
http://www.grandviewresearch.com/industry-analysis/biomarkers-industry
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.